Prostate cancer and prostatic diseases · 2024
Genomic attributes of prostate cancer across primary and metastatic noncastrate and castrate resistant disease states: a next generation sequencing study of 183 patients.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dasari Surendra, McCarthy Michael R, Wojcik Antonina A, Pitel Beth A, Samaddar Arpan, Tekin Burak, Whaley Rumeal D, Raghunathan Aditya, Hernandez Loren Herrera, Jimenez Rafael E, Stish Brad J, Thompson R Houston, Leibovich Bradley C, Boorjian Stephen A, Jeffrey Karnes R, Childs Daniel S, Quevedo J Fernando, Kwon Eugene D, Pagliaro Lance C, Costello Brian A, Halling Kevin C, Cheville John C, Kipp Benjamin R, Gupta Sounak
Аннотация
Primary prostatic adenocarcinoma (pPC) undergoes genomic evolution secondary to therapy-related selection pressures as it transitions to metastatic noncastrate (mNC-PC) and castrate resistant (mCR-PC) disease. Next generation sequencing results were evaluated for pPC (n = 97), locally advanced disease (involving urinary bladder/rectum, n = 12), mNC-PC (n = 21), and mCR-PC (n = 54). We identified enrichment of TP53 alterations in high-grade pPC, TP53/RB1 alterations in HGNE disease, and AR alterations in metastatic and castrate resistant disease. Actionable alterations (MSI-H phenotype and HRR genes) were identified in approximately a fifth of all cases. These results help elucidate the landscape of genomic alterations across the clinical spectrum of prostate cancer.